Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy.
Breast cancer
Cancer therapy
Journal
NPJ breast cancer
ISSN: 2374-4677
Titre abrégé: NPJ Breast Cancer
Pays: United States
ID NLM: 101674891
Informations de publication
Date de publication:
2019
2019
Historique:
received:
25
05
2019
accepted:
25
09
2019
entrez:
16
11
2019
pubmed:
16
11
2019
medline:
16
11
2019
Statut:
epublish
Résumé
The 21-gene Recurrence Score (RS) assay is a validated prognosticator/predictor of chemotherapy (CT) benefit in early-stage estrogen receptor (ER)-positive breast cancer (BC). Long-term data from real-life clinical practice where treatment was guided by the RS result are lacking. We performed exploratory analysis of the Clalit Health Services (CHS) registry, which included all CHS patients with node-negative ER+ HER2-negative BC who underwent RS testing between 1/2006 and 12/2009 to determine 10-year Kaplan-Meier estimates for distant recurrence/BC-specific mortality (BCSM) in this cohort. The analysis included 1365 patients. Distribution of RS results: RS 0-10, 17.8%; RS 11-25, 62.5%; RS 26-100, 19.7%. Corresponding CT use: 0, 9.4, and 69.9%. Ten-year distant recurrence rates in patients with RS 0-10, 11-25, and 26-100: 2.6% (95% confidence interval [CI], 1.1-6.2%), 6.1% (95% CI, 4.4-8.6%), and 13.1% (95% CI, 9.4-18.3%), respectively (
Identifiants
pubmed: 31728408
doi: 10.1038/s41523-019-0137-3
pii: 137
pmc: PMC6841708
doi:
Types de publication
Journal Article
Langues
eng
Pagination
41Informations de copyright
© The Author(s) 2019.
Déclaration de conflit d'intérêts
Competing interestsS.M.S. reports receiving grant funding from Teva; receiving travel expenses from Genomic Health, Inc.; conducting research funded by Teva. N.B. reports receiving honoraria from Teva, and serving on the speaker’s bureau of Genomic Health. D.M.J., J.B., and S.S. report being employed by Genomic Health. D.M.J., J.B., and S.S. report having stock ownership in Genomic Health. S.S. reports having intellectual property interest in Genomic Health and a leadership role at Genomic Health. L.S.G. reports being employed by and holding stock options in Teva Pharmaceutical Industries Ltd. A.B.S. reports being a consultant/medical writer for Teva Pharmaceutical Industries Ltd., Genomic Health Inc. (including for the purpose of the current study), Bayer, and Roche. M.S., S.R., B.U., G.F., O.R., A.I., B.N., D.K., M.L., M.T., N.L., and D.B.G. declare no competing interests.
Références
N Engl J Med. 2004 Dec 30;351(27):2817-26
pubmed: 15591335
J Clin Oncol. 2016 Jul 10;34(20):2341-9
pubmed: 26926676
NPJ Breast Cancer. 2018 Nov 14;4:37
pubmed: 30456299
NPJ Breast Cancer. 2019 Nov 8;5:41
pubmed: 31728408
J Clin Oncol. 2006 Aug 10;24(23):3726-34
pubmed: 16720680
J Clin Oncol. 2010 Apr 10;28(11):1829-34
pubmed: 20212256
N Engl J Med. 2018 Jul 12;379(2):111-121
pubmed: 29860917
N Engl J Med. 2017 Nov 9;377(19):1836-1846
pubmed: 29117498
Mod Pathol. 2006 Feb;19(2):195-207
pubmed: 16341153
NPJ Breast Cancer. 2017 Sep 8;3:33
pubmed: 28900633
N Engl J Med. 2019 Jun 20;380(25):2395-2405
pubmed: 31157962
Breast Cancer Res Treat. 2017 Oct;165(3):573-583
pubmed: 28664507
Cancer. 2019 Jan 15;125(2):213-222
pubmed: 30387876
J Clin Oncol. 2016 Jul 10;34(20):2350-8
pubmed: 27217450
Rep Pract Oncol Radiother. 2012 Jul 15;18(1):26-33
pubmed: 24381744